CRISPR-Cas9 Technology and Genetic Engineering

Biography

Hamutal Meiri, PhD, MBA has a BSc degree in Biology from Ben-Gurion University (1973), an MBA degree from the Tel Aviv University School of business management (1995) and a PhD from the Hebrew University in Neurosciences (1980). She was a post-doc fellow of the Weil-Cornell Med. College in Neuroscience, and has been a faculty member of the Dep. of Physiol. & Pharmacol at Tel Aviv University School of Medicine, and of Physiol. & Biophys. at the Technion, Rappaport Faculty of Medicine. She was also a Visiting Prof. at Pharmacology at Columbia University College of Physicians & Surgeons, in the Psychiatric Research at Mount Sinai hospitals and in Pharmacology at New York University School of Medicine. In Telemedicine she established and chaired Israel Telemedicine Forum and served as the first Director of the Israel National Committee of Biotechnology. Dr. Meiri was a Director of a Chief Scientist 's Biotechnology Consortium, the Director of the North Carolina-Israel Science and Technology Fund, and the CEO of Diagnostic Technologies Ltd. in fetal medicine. She is currently the CEO and Chairman of the Board of TeleMarpe Ltd., and a consultant to the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) in Neurotech. Between 2006-2010 she was the coordinator of FP6 project Pregenesys. In 2012 she joined project NanoAthero (FP7). In 2013 she became the exploitation Director of Project ASPRE (FP7). ASPRE was completed with a major publication in the NEJM published June 28, 2017

Research Interest

Dr. Hamutal Meiri is engaged in Project Obediome (BIRD-F) comparing the microbiome of slim and obese/diabetics and the impact of bariatric surgery. The study has no expanded to compare obese diabetic of China, Israel and the USA via China-Israel MOST project. In fetal medicine she is engaged in in developing DNA/RNA based molecular biomarkers to predict preeclampsia and the design of novel therapies such as Eclampsin to fight preeclampsia